Compare ARK Genomic Revolution ETF (ARKG) vs Core and Main Inc (CNM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Core and Main Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Core and Main Inc trades at $45.86 (market cap $8.58B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Core and Main Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | CNM | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $66.98 |
52-Week Low | $23.09 | $44.29 |
Market Cap | — | $8.58B |
Enterprise Value | — | $10.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Core & Main (CNM) trades at $45.86, showing a 1.44% daily gain amid a bearish technical outlook. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $0.72 exceeding expectations. Fundamentally, the company maintains solid profitability with a 5.87% net margin and 23.73% ROE, though valuation metrics appear elevated with a P/E of 19.43. Recent news highlights the company's senior notes offering and resilient municipal demand despite residential weakness.
The outlook remains cautiously optimistic with analyst consensus favoring Buy ratings (57%), but technical indicators signal near-term pressure. Key opportunities include strong municipal business performance and margin expansion, while risks involve high debt levels and industry headwinds. The stock's current position near support at $45 suggests potential for consolidation before next earnings catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Core and Main Inc
Core & Main is a leading US distributor of water, wastewater, storm drainage, and fire protection products. It provides essential infrastructure solutions to municipalities, private water companies, and contractors.
Read more on CNM →
